210 related articles for article (PubMed ID: 24350725)
21. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.
Dervieux T; Furst D; Lein DO; Capps R; Smith K; Caldwell J; Kremer J
Ann Rheum Dis; 2005 Aug; 64(8):1180-5. PubMed ID: 15677700
[TBL] [Abstract][Full Text] [Related]
22. Hyperhomocysteinemia in rheumatoid arthritis: influence of methotrexate treatment and folic acid supplementation.
Jensen OK; Rasmussen C; Mollerup F; Christensen PB; Hansen H; Ekelund S; Thulstrup AM
J Rheumatol; 2002 Aug; 29(8):1615-8. PubMed ID: 12180718
[TBL] [Abstract][Full Text] [Related]
23. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.
Whittle SL; Hughes RA
Rheumatology (Oxford); 2004 Mar; 43(3):267-71. PubMed ID: 14963199
[TBL] [Abstract][Full Text] [Related]
24. Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients.
Moya P; Salazar J; Arranz MJ; Díaz-Torné C; del Río E; Casademont J; Corominas H; Baiget M
Pharmacogenomics; 2016; 17(1):25-9. PubMed ID: 26652611
[TBL] [Abstract][Full Text] [Related]
25. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis.
Dervieux T; Wessels JA; van der Straaten T; Penrod N; Moore JH; Guchelaar HJ; Kremer JM
Pharmacogenet Genomics; 2009 Dec; 19(12):935-44. PubMed ID: 19858780
[TBL] [Abstract][Full Text] [Related]
26. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.
Hayashi H; Tazoe Y; Tsuboi S; Horino M; Morishita M; Arai T; Ohshima M; Matsuyama T; Kosuge K; Yamada H; Tsuji D; Inoue K; Itoh K
Drug Metab Pharmacokinet; 2013; 28(2):164-8. PubMed ID: 22971639
[TBL] [Abstract][Full Text] [Related]
27. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.
Takatori R; Takahashi KA; Tokunaga D; Hojo T; Fujioka M; Asano T; Hirata T; Kawahito Y; Satomi Y; Nishino H; Tanaka T; Hirota Y; Kubo T
Clin Exp Rheumatol; 2006; 24(5):546-54. PubMed ID: 17181924
[TBL] [Abstract][Full Text] [Related]
28. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis.
Weisman MH; Furst DE; Park GS; Kremer JM; Smith KM; Wallace DJ; Caldwell JR; Dervieux T
Arthritis Rheum; 2006 Feb; 54(2):607-12. PubMed ID: 16447238
[TBL] [Abstract][Full Text] [Related]
29. Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis.
Castaneda O; Nair MG
J Rheumatol; 2006 May; 33(5):862-4. PubMed ID: 16652417
[TBL] [Abstract][Full Text] [Related]
30. Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients.
Lima A; Seabra V; Bernardes M; Azevedo R; Sousa H; Medeiros R
PLoS One; 2014; 9(10):e108165. PubMed ID: 25279663
[TBL] [Abstract][Full Text] [Related]
31. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.
Kurzawski M; Pawlik A; Safranow K; Herczynska M; Drozdzik M
Pharmacogenomics; 2007 Nov; 8(11):1551-9. PubMed ID: 18034620
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
[TBL] [Abstract][Full Text] [Related]
33. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate.
Kim SK; Jun JB; El-Sohemy A; Bae SC
J Rheumatol; 2006 Jul; 33(7):1266-74. PubMed ID: 16758511
[TBL] [Abstract][Full Text] [Related]
35. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
[TBL] [Abstract][Full Text] [Related]
36. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention.
Morgan SL; Baggott JE; Lee JY; Alarcón GS
J Rheumatol; 1998 Mar; 25(3):441-6. PubMed ID: 9517760
[TBL] [Abstract][Full Text] [Related]
37. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
[TBL] [Abstract][Full Text] [Related]
38. The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.
Nomair AM; Abdelati A; Dwedar FI; Elnemr R; Kamel YN; Nomeir HM
Clin Rheumatol; 2024 Mar; 43(3):971-983. PubMed ID: 38311638
[TBL] [Abstract][Full Text] [Related]
39. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.
Wessels JA; Kooloos WM; De Jonge R; De Vries-Bouwstra JK; Allaart CF; Linssen A; Collee G; De Sonnaville P; Lindemans J; Huizinga TW; Guchelaar HJ
Arthritis Rheum; 2006 Sep; 54(9):2830-9. PubMed ID: 16947783
[TBL] [Abstract][Full Text] [Related]
40. Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.
de Rotte MC; de Jong PH; Pluijm SM; Calasan MB; Barendregt PJ; van Zeben D; van der Lubbe PA; de Sonnaville PB; Lindemans J; Hazes JM; de Jonge R
Arthritis Rheum; 2013 Nov; 65(11):2803-13. PubMed ID: 24166792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
